Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
We propose to evaluate ixabepilone in combination with cyclophosphamide for the neoadjuvant
treatment of locally advanced breast cancer. In this regimen, ixabepilone is substituted for
docetaxel, since preclinical and clinical
studies suggest that ixabepilone is more active than either docetaxel or paclitaxel. The
combination of ixabepilone and cyclophosphamide could further improve the efficacy of
non-anthracycline neoadjuvant therapy.